Cenobamate-associated weight loss (Cenobaweight study)
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cenobamate (CNB) use in epilepsy patients is linked to significant unintentional weight loss in a notable number of individuals. Dose reduction may reverse this effect without worsening seizures.
Area Of Science
- Neurology
- Clinical Pharmacology
Background
- Limited data exists on weight changes associated with Cenobamate (CNB).
- Concerns regarding clinically significant weight loss prompted this case-control study.
Purpose Of The Study
- To evaluate weight changes in patients with epilepsy treated with Cenobamate.
- To assess the incidence and potential reversibility of weight loss associated with CNB.
Main Methods
- A case-control study evaluated 118 epilepsy patients with at least 180 days of CNB exposure.
- Baseline weight, trough, and peak weights during CNB treatment were recorded.
- Concomitant antiseizure medications (ASMs) were also documented.
Main Results
- 27.8% of patients experienced at least 10% weight loss; 5.1% had ≥20% weight loss.
- Higher CNB doses (≥200 mg/d) were associated with greater weight loss.
- Weight loss effects appeared reversible with dose reduction in some patients, without seizure exacerbation.
Conclusions
- A significant number of patients experienced unintentional weight loss with CNB use.
- Weight loss may be reversible with CNB dose reduction.
- Systematic weight monitoring is recommended for all patients on CNB, with consideration for dose adjustment if excessive weight loss occurs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...